In order to determine geographically related intratypic variation in human papillomavirus (HPV) type 16 and 18 isolates that could be associated with lesion development, data were analysed from an ongoing cohort study of the natural course of infection of HPVs and cervical neoplasia. Testing for HPVs was carried out by PCR and molecular variants of these HPVs were characterized by sequence analysis of the long control region and by dot blot hybridization of the E6 and L1 genes. Tests for HPV were done in multiple first-year specimens from 1690 women enrolled in a cancer screening program from 1993 to 1997. Subjects were followed-up by cytology and cervicography for detection of cervical lesions. Seven variants of HPV-16 and four of HPV-18 were detected in one or more specimens from 65 subjects. The same variant was found in specimens taken on different visits from each case of persistent infection. Overall, non-European variants tended to persist more frequently [odds ratio (OR) l 4n5 ; 95 % confidence interval (CI), 1n6-12n4] than European (E) variants (OR l 2n5 ; 95 % CI, 1n3-4n9), relative to the risk of persistence for nononcogenic HPVs. In addition, non-E variants were more strongly associated with risk of both prevalent (age-and race-adjusted OR l 172n2 ; 95 % CI, 47n1-630n1) and incident [relative risk (RR) l 22n5 ; 95 % CI, 6n0-83n9] high-grade lesions than E variants (prevalent lesions OR l 46n3; 95 % CI, 15n5-138n0 and incident lesons RR l 6n1 ; 95 % CI, 1n3-27n4), relative to the risk for HPVnegative women. Although consistent, the latter differences were not statistically significant. If confirmed in other populations, measurement of intratypic variation of HPV-16 and -18 has the potential to serve as an ancillary tool in cervical cancer screening.
Introduction
Studies using DNA sequencing analyses of hundreds of isolates of human papillomaviruses (HPVs) from clinical HPVs have co-evolved with their natural hosts over a period of several million years. Data obtained from 25 different geographical regions in the world indicate that HPV-16 has evolved along five major branches, two being present mainly in Africa, two in Asia, and one in Europe and India (L. Ho et al., 1993 ; Ong et al., 1993) . These studies revealed that colonization of the New World by Europeans and Africans is reflected in the distribution of HPV-16 variants in the American continent. It also became clear that these variants represent genuine HPV genomes since they have been found in different individuals from different regions around the world. Furthermore, variation studies performed on the long control region (LCR), E6, L1 and L2 genes of HPV-16 indicate that recombination between variants is either rare or non-existent (L. Ho et al., 1993 ; Yamada et al., 1995 Yamada et al., , 1997 .
Few nucleotide differences found in HPV variants correspond to changes in amino acids. Nevertheless, it is of great interest to define alterations that may interfere with the functional or antigenic properties of specific viral proteins. For instance, variant 114K of HPV-16 assembles into virus-like particles (VLP) in a heterologous expression system, whereas the reference (prototype) clone of HPV-16 does not have the same property (Kirnbauer et al., 1992 (Kirnbauer et al., , 1993 . This difference has been attributed to a single amino acid change at residue 202 (Asp to His) of the L1 gene. Other changes in the L1\L2 regions of the HPV genomes may be important for discriminating between the infectious potential of different variants as well as in defining epitopes relevant to vaccine design. It has also been reported that a specific variation in the HPV-16 E6 protein, isolated from cervical cancers of HLA-B7 individuals, interferes with the T-cell cytotoxic immune response (Ellis et al., 1995) .
In studies examining the course of HPV infection and the role of the virus in the genesis of cervical cancer, issues such as polyclonality of lesions and frequency of particular HPV variants may be critical to our understanding of virus infectivity and pathogenicity (Zehbe & Tommasino, 1999) . Nucleotide sequence variation has been used as an important tool for epidemiological studies of virus transmission and persistence (Franco et al., 1994) . The utility of this approach was indicated in a study of the sexual transmission of HPV-16 (G. Ho et al., 1993) . In a cohort study of young women, Xi et al. (1995) found 16 different HPV-16 variants, one of which persisted over time, while the other variants were transiently detected. In addition, intratypic variation of HPV-16 has also been shown to be an important predictor of progression to clinically relevant cervical lesions (Xi et al., 1997) .
In this report, we present results from an ongoing study of the natural course of HPV infection and cervical neoplasia in Brazil showing the association between variants as defined by geographical relatedness and characteristics of the infection and lesion development. Unlike most previous studies, we have analysed variants of both HPV-16 and -18 and assessed their correlation with virus persistence and virus burden as well as with risk of prevalent and incident pre-invasive lesions.
Methods
Study cohort. Details of the Ludwig-McGill cohort study have been presented elsewhere (Franco et al., 1999 a, b) . Since 1993, women enrolled in a cancer screening program catering for low-income families in Sa4 o Paulo, Brazil have been followed-up in scheduled returns every 4 months in the first year post-enrolment (0, 4, 8 and 12 months) and once every 6 months thereafter. In each of these visits, a questionnaire-based interview was carried out. Subjects also had a cervical specimen taken for Pap cytology and HPV testing and a blood sample was drawn for serologic testing for HPV antibodies. A cervicography was performed once in the first year and every 2 years thereafter. This investigation was approved by ethical review boards of the authors' institutions.
Cervical cell specimens. An Accelon biosampler (Medscand) was used to collect a sample of ectocervical and endocervical cells at each of the visits. After the smear was prepared on a glass slide and fixed in 95 % ethanol, the exfoliated cells remaining in the sampler were immersed in a tube containing Tris-EDTA buffer pH 7n4, kept at 4 mC at the clinic for at most 5 days, and then frozen until testing. Cervical smears were sent to Montreal and were evaluated by the Bethesda system. Cytology readings were done blindly (A. F.).
HPV DNA detection and typing. Cervical specimen DNA was extracted and purified following standard techniques. In brief, cells were digested with 100 µg\ml proteinase K for 3-18 h at 55 mC and the DNA was purified by spin-column chromatography. Specimens were tested for the presence of HPV DNA by a previously described PCR protocol amplifying a highly conserved 450 bp segment in the L1 viral gene (flanked by primers MY09\11). Typing of the amplified products was performed by hybridization with individual oligonucleotide probes specific for 27 HPV genital types (Bauer et al., 1991 ; Hildesheim et al., 1994) . Amplified products hybridizing to the generic probe but not to any of the type-specific probes were further tested by restriction fragment length polymorphism analysis (Bernard et al., 1994 b) . This extends the range of identifiable HPVs to over 40 genital types. In order to check the integrity of the host DNA material extracted from the specimens, assays also included an additional set of primers (GH20 and PC04), which amplify a 268 bp region of the human β-globin gene (Saiki et al., 1988) . In most analyses, infections with HPV-16 and -18 were considered together and the remaining HPV types were grouped according to their oncogenic potential. We followed the classification scheme of Liaw et al. (1999) , which grouped as oncogenic types and considered all other HPV types (except HPV-16 and -18) as non-oncogenic. Unknown types were included in the latter group.
Determination of virus load. We measured virus load in the cervical specimens by a quantitative PCR protocol as previously described (Caballero et al., 1995) . This test consists of employing low stringency conditions to allow co-amplification of the specific HPV DNA fragment along with certain DNA sequences from the human genome present in the starting mixture. After amplification, the ratio of the specific HPV band to that of the host genome internal band was measured by densitometry and followed by quantification via interpolation from a standard curve ; the standard curve was prepared with pre-selected amounts of reference HPV plasmid added to a constant background of normal human DNA (Caballero et al., 1995 ; Villa et al., 1996) .
HPV variants and risk of cervical neoplasia HPV variants and risk of cervical neoplasia
Molecular variant analysis. We tested for molecular variants of HPV-16 and -18 using a PCR sequencing method (Ho et al., 1991 ; Ong et al., 1993) . A 364 bp segment (nt 7478-7841) or a 321 bp segment (nt 7464-7825) within the HPV-16 or HPV-18 LCR, respectively, was amplified as previously described (Franco et al., 1994 ; Villa et al., 1997) . The PCR products were cloned using the SureClone ligation kit (Pharmacia) and transformed into E. coli, strain XL1-Blue. Recombinant plasmid DNAs were isolated from positive clones and sequenced by automated DNA sequencing in an Alfie Express sequencing machine (Pharmacia). To prevent errors due to possible misincorporation of bases by Taq DNA polymerase a minimum of five clones was sequenced for each isolate. This also allowed the identification of multiple co-existing variants. Variants were grouped within branches of geographical relatedness based on the nucleotide difference profiles (L. Ho et al., 1993 ; Ong et al., 1993) . These variant branches are designated as E (European), As (Asian), AA (Asian-American) and Af (African).
Most specimens were also tested by a recently described hybridization procedure that allows the detection of all previously described variant groups of HPV-16 . This approach focuses on the joint variability in the E6 and L1 genes and allows the classification of these variants into two additional subclasses within the E and AA branches (Yamada et al., 1995) .
Statistical analysis.
We analysed persistence of HPV infection throughout the first year of follow-up (up to four visits) of HPV-16 and -18 variants and other grouped types using logistic regression. Persistent infection was defined as a case with two or more positive visits for the same HPV type, consecutive or not. We computed two separate logistic models including co-variant adjustment for age and race to estimate odds ratios (OR) and their respective 95 % confidence intervals (95 % CI) for persistence : one in which variants of both HPV-16 and -18 were classified together and another in which only variants of HPV-16 were grouped by geographical relatedness.
We used Student's t-test to compare the mean virus burden in HPVpositive cervical specimens by grouped HPV-16 and -18 variants and other types based on oncogenicity. To obtain normally distributed groups for comparison, the logs were taken of individual copy numbers per cell obtained by quantitative PCR. We contrasted the mean in each group separately against those of non-oncogenic types and against those of E branch variants of HPV-16 and -18. We computed geometrical mean copy numbers and respective 95 % CI per group by pooling the results from all four visits using a weighted method to combine the variances in order to account for non-independence of observations. Risk of cervical lesions according to grouped HPV-16 and -18 variants and other types based on oncogenicity was analysed in two ways. First, we analysed the association between HPV-infection status as cumulative exposure during all first year visits and any detection of squamous intraepithelial lesions (SILs) during the same period, but not during subsequent follow-up visits. Logistic regression models were computed to estimate OR (and 95 % CI) of SILs. Second, we analysed the risk of post-enrolment occurrence of SILs as an incident finding by considering only women free of SILs at the enrolment visit in relation to HPVinfection status at enrolment. Cox proportional hazards regression models were computed to estimate relative risks (RR) and 95 % CI of incident SILs by HPV-infection status. Three non-mutually exclusive outcomes were used in both logistic and Cox analyses : any grade SIL, high-grade SIL (HSIL) and an augmented HSIL definition that included detection by cervicography in addition to cytology. As in the analysis of persistence above, estimates of effect (OR and RR) were computed in separate models : one in which variants of both HPV-16 and -18 were classified together and another in which only variants of HPV-16 were grouped by geographical relatedness. OR and RR values were adjusted for age and ethnicity.
Results
The 1690 participants included in this analysis represented mostly those women admitted early in the study (a total of 2528 women were enrolled in the cohort with a 70 % response rate). At the time of the analysis only cervical specimens from the first year post-enrolment had been tested for HPV. A total of 6077 tests for HPV, an average of 3n6 tests per subject, were performed. Of these tests, 173 were non-informative because of failure to amplify the β-globin gene (2n8 %). The median age of participants was 33 years (mean l 33 ; 1st and 3rd quartiles, 26 and 39 years, respectively). Data were available until November 1999 for lesion surveillance via cytology and cervicography, for a total of 69 190 woman-months of followup (average of 40n9 months per subject).
A total of 443 women had one or more positive results for HPV (26n2 %), 92 of which were positive for variants of HPV-16 or -18, 175 were positive for other oncogenic types and 176 were positive exclusively for non-oncogenic HPVs. Using LCR sequence analysis, we have characterized 97 isolates of HPV-16 from 54 subjects, and 25 HPV-18-positive samples from 12 subjects (one of them with both HPV-16 and -18). We identified seven different molecular variants of HPV-16 belonging to all four branches of geographical and phylogenetic relatedness. The prototype of HPV-16, which is classified in the E branch, was the most frequent isolate (29 of 54 subjects, 54 %), followed by variant B-2 from the AA branch (12 of 54 subjects, 22 %). Two subjects harboured novel variants with nucleotide patterns comparable to the latter variant. Regarding HPV-18 isolates, we found four variants that were classifiable only in the E and Af branches. The B18-2 variant (E branch) was the most common finding (8 of 12 subjects, 67 %). The one subject infected with both HPV-16 and -18 for whom variant analysis was completed harboured variants that were classifiable in the E branch for both of these types. There was only one subject with HPV-18 classifiable in the Af branch (variant T18-7), and no subjects were infected with the prototype strain. This precluded a separate presentation of results for this type in the analysis of persistence and lesion risk.
The above analysis based on the LCR region was extended by a search for mutations in the E6 and L1 genes (Fig. 1) . This analysis allowed us to corroborate the variant classification based on LCR (data not shown) and permitted the classification of the two novel HPV-16 isolates into the North-American-1 sub-class of the AA branch, given their pattern of nucleotide substitutions in the E6 and L1 genes.
Cases of persistent infection with HPV-16 or -18 always had the same molecular variant in all positive specimens, irrespective of the number of clones that were tested. We also searched for multiple infections of different variants of the same HPV type in all isolates. We did not find a single case Ho et al. (1993) and for HPV-16 at nt 7477-7842 and (d) Ong et al. (1993) for HPV-18 at nt 7484-7805. The variability in genes (a) L1 at nt 6598-7021 and (c) E6 at nt 56-640 were analysed according to . with more than one variant of HPV-16 or -18 based on a search of a minimum of five clones per isolate. Table 1 shows the age-and race-adjusted OR values of persistent infection by HPV-infection status based on up to four results during the first year of follow-up. Between HPV-16-and -18-positive cases, 39 (60 %) were classified as persistent. Among individuals infected exclusively with lowrisk types, persistent infection was less common (34 %). Taking the latter as the reference category, persistent infections were significantly more common among women harbouring HPV-16 and -18 or other oncogenic types. A somewhat stronger association with persistence seemed to emerge for HPV-16 and -18 variants or, when considered alone, for HPV-16 variants of non-E branches (AA, Af, As) as compared to E branch variants, although the 95 % CI values overlapped extensively. (36) 2n8 (1n4-5n7) 0n1737 0n6487
Other oncogenic types (272) 9n5 (6n5-13n9) 0n2169 0n0001
Only non-oncogenic types (267) 2n3 (1n7-3n1) 0n0041 - HPV-infection status. Specimens with other oncogenic types had the highest average viral genome counts (9n5 per cell). Despite the higher copy frequency for E branch variants as compared to non-E branch variants of HPV-16 and -18, the difference in virus load did not reach statistical significance (P l 0n174). However, infections with E branch variants were significantly more productive than those with only nononcogenic types (P l 0n0041), whereas virus load for the latter infections and that for non-E branch variants were virtually indistinguishable (2n3 versus 2n8, respectively, P l 0n649). Table 3 shows the logistic regression analyses of prevalent cervical lesions by HPV-infection status using cumulative data from the entire first year of follow-up. Strong and significant associations for all HPV-infection categories were found for any grade SIL and HSIL, regardless of the outcome definition. It is noteworthy that the magnitude of the associations was greatest for non-E branch variants of combined HPV-16 and -18 or HPV-16 alone in all outcome definitions. In most combinations, however, the 95 % CI values overlapped substantially. The sole exception was the contrast based on HSIL assessed jointly by cytology and cervicography for which the OR for non-E branch variants of HPV-16 and -18 was significantly greater than that for E branch variants (P l 0n045). Table 4 also shows associations between HPV-infection status and lesion outcomes based on similar comparisons to those presented in the previous analysis except that lesion outcomes were defined prospectively in a true cohort fashion and estimates of effect (RR) were assessed via proportional hazards regression models. All prevalent lesions at enrolment were excluded. As above, RR values of lesion development were substantially elevated for HPV-infection categories involving oncogenic HPV types, with the greatest increase in risk being observed for non-E branch variants. As above, however, the increased risk for non-E branch variants was not statistically significant (at the 5 % level) as compared to that calculated for the E branch variants in any of the combinations analysed.
Discussion
In this study we have detected several variants of HPV-16 and -18 in cervical specimens from asymptomatic women living in a high-risk area for cervical cancer in Brazil. We CJGE searched for genetic variation in a fragment of the LCR by DNA sequencing, as well as in the E6 and L1 genes by dot blot hybridization. The LCR is a hypervariable region of the viral genome, thus theoretically enabling the detection of a greater diversity of variants than when conserved genes are analysed . Analysis of defined segments of other genes, such as E2, E5, E6, L1 and L2, has also been shown to indicate substantial diversity in molecular variants of HPV-16 (Eriksson et al., 1999 ; Icenogle et al., 1991 ; Yamada et al., 1995 ; .
All cases with persistently detected HPV-16 and -18 had the same variant in multiple specimens collected at different points in time. Although we always tested a minimum of five clones per isolate we did not find multiple variants in the same specimen, which is in disagreement with previous reports (L. Ho et al., 1991 Ho et al., , 1993 Xi et al., 1995 ; . Interestingly, Xi et al. (1995) noticed that one variant prevails over the other in women with multiple infections of HPV-16 variants. Polyclonality of variants of HPV-16 has been more frequently found in cancers (L. Ho et al., 1993 ; Nindl et al., 1999) . In fact, in a survey of HPV-16-positive invasive cervical cancers from Bele! m (Northern Brazil) we have been able to detect more than one variant in about 10 % of the cases (Junes et al., 2000) .
Although little is known about the direct biological consequences of variations in the HPV genomes on cervical carcinogenesis, it is reasonable to anticipate that they may be relevant to different aspects of this process. Several reports suggest that some variants of HPV-16 are associated with risk of cervical neoplasia. Londesborough et al. (1996) , studying genetic variability in the HPV-16 E6 gene in a cohort of women from England, described a T to G substitution at nt 350 that was predominantly associated with virus persistence and risk of cervical neoplasia. Another study reported that a nucleotide change at nt 647 of the E7 gene of HPV-16 was more frequently found in cervical carcinomas (Song et al., 1997) . Modification of this residue, involved in the binding of E7 to pRb, could have important functional implications.
Of direct relevance to our ongoing investigation were the findings of Xi et al. (1997) . These authors analysed a fragment of the HPV-16 LCR by single-strand conformation polymorphism analysis in cervical specimens from young American women. They observed that non-prototype-like (NPL) variants were more strongly associated with the development of cervical lesions than prototype-like (PL) variants. Similar results were observed in a series of anal carcinomas where NPL variants were more prevalent than the HPV-16 PL variants (Xi et al., 1998) . Since the HPV-16 prototype is classified as an E branch variant, based on geographical and phylogenetic relatedness, we hypothesized that the differences in risk attribution between NPL and PL variants found in the latter studies could be indicative of broad differences in the ability to induce cervical carcinogenesis by oncogenic HPVs from different geographical areas. We sought to test this hypothesis by searching for molecular variants in different genome regions using sequencing (LCR) corroborated with direct oligonucleotide probing (E6 and L1). Unlike Xi et al. (1997) , we grouped our variant findings according to geographical relatedness based on a well-established classification system (L. Ho et al., 1993 ; Ong et al., 1993 ; Yamada et al., 1995) . We also extended the analysis to include HPV-18 in addition to HPV-16.
Our results are consistent with the aforementioned hypothesis and tend to corroborate the results of Xi et al. (1997) . We found that infections with non-E branch variants of HPV-16 and -18 have a general tendency to persist more frequently and to be more associated with pre-invasive lesions, both cross-sectionally and prospectively. These results were not a consequence of follow-up bias since women with E branch and non-E branch infections were comparable in terms of follow-up time (P l 0n697), number of HPV tests (P l 0n896) and number of Pap tests (P l 0n889) or cervicographies (P l 0n407) during follow-up.
An important limitation of our study was the relatively low ability to detect these associations. An additional caveat is the fact that our definition of lesion outcomes was based on cytology and\or cervicography and not on histology. Our ongoing cohort study relies on cytologic and cervicography follow-up with biopsy required only of HSIL lesions that are seen on colposcopy in association with lesional tissue. However, the fact that the findings were consistent across definitions of lesion outcomes and analysis layouts (crosssectional versus prospective) and that we have observed the increased risk associated with non-E variants since earlier phases of our cohort study bolsters our confidence that the association may be real and worthy of consideration for disease prevention purposes. It is also conceivable that the magnitude of the associations would have been much greater if we had used histological ascertainment of all lesions detected in the study, an observation that we will make at a later phase of the investigation after substantially more cases of HPV-16 and -18 infections are accrued in the cohort.
The distribution of HPV variants defined on the basis of geographical relatedness may be expected to be associated with ethnicity. Since the latter variable is a correlate of cervical cancer risk, a confounded association between variant grouping and lesion risk may occur empirically. In the present analysis, 15 of 46 women (33 %) infected with E branch variants were non-white (mostly black and mulatto ethnicity) as compared to 11 of 19 women (58 %) infected with non-E branch variants in the same ethnic category. Although the difference fails to reach statistical significance (P l 0n058), the imbalance in ethnic distribution is sufficient to warrant confusion assuming that race is a correlate of the outcome in our cohort (data not shown). This observation underscores the importance of conducting analyses that are appropriately adjusted for race when gauging the association between variant grouping and lesion risk. We controlled for both ethnicity and age in our CJGF models of the relationships under investigation. We cannot completely rule out, however, a residual confounding influence of race on the results because of the extensive admixture of ethnic groups in the Brazilian population.
The differential oncogenic potential associated with certain variants has been addressed (Hecht et al., 1995 ; ConradSto$ ppler et al., 1996 ; Veress et al., 1999 ; Ka$ mmer et al., 2000) . Research in this area is anticipated to provide important information concerning the biological significance of HPV intratype genomic variability, which could ultimately be used to address the control of these infections. Changes in the L1\L2 regions of the HPV genome may be important in discriminating the infectious potential of different variants, as well as in defining epitopes relevant to vaccine design. Our knowledge about the amino acid residues that are involved in antigenic recognition of HPV is very limited. It has been shown that naturally occurring antibodies against L1, the major viral capsid protein, are directed to conformational epitopes (Kirnbauer et al., 1994 ; Rose et al., 1994) . However, little is known about the influence of HLA haplotypes on the host immune response. HLA haplotypes seem to be important determinants of susceptibility to cervical cancer and may represent an important aspect for understanding cervical carcinogenesis (Maciag & Villa, 1999) . Recent research on the role of both HLA (Ellis et al., 1995 ; Terry et al., 1997 ; Bontkes et al., 1998) and p53 polymorphisms (van Duin et al., 2000) indicates that susceptibility to cervical cancer may depend on the particular variant of HPV-16 to which the woman was originally exposed.
Cervical cancer incidence is much higher in Africa and Latin American countries than in Europe and North America. There is little doubt that ineffective or non-existent screening, lack of access to health care, high fertility and poor nutrition explain many of the differences in rates between these underdeveloped and developed areas. It is also important to realize that non-E variants of HPV-16 and -18 may have increased oncogenic potential and may represent an additional factor contributing to the disproportionately high burden of cervical cancer in underdeveloped populations in different regions of the world.
